Oncotelic Therapeutics (OTCQB: OTLC), through its wholly owned subsidiary Pet2DAO, Inc., has opened registration for BIO REBOOT, a collaborative initiative powered by its PDAOAI artificial intelligence platform. The program invites scientists, AI developers, and biotech founders to bring research questions, technical expertise, and drug discovery ideas to the PDAOAI community. Selected projects may receive startup funding and support from Oncotelic covering validation, formulation, regulatory planning, and clinical development. This move signals a strategic shift toward decentralized, AI-driven drug discovery, potentially accelerating the development of novel therapies and lowering barriers for early-stage innovators.
The company also announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study demonstrating how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations underscore the growing role of AI in identifying biomarkers and streamlining research, which could lead to more targeted and effective cancer treatments.
Oncotelic Therapeutics develops oncology and immunotherapy products, focusing on cancers with substantial unmet needs and rare pediatric indications. The PDAOAI platform supports its drug discovery and development efforts. By opening BIO REBOOT to external participants, Oncotelic aims to leverage collective intelligence to speed up innovation, potentially transforming how oncology drugs are discovered and developed. For investors, this initiative could enhance the company's pipeline and partnerships, while for the broader biotech sector, it represents a model for collaborative AI-driven research.
The full press release can be viewed at https://ibn.fm/dxB7y. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
